Yayınlar & Eserler

Makaleler 132
Tümü (132)
SCI-E, SSCI, AHCI (96)
SCI-E, SSCI, AHCI, ESCI (99)
ESCI (3)
Scopus (96)
TRDizin (58)
Diğer Yayınlar (4)

118. Pulmonary Complications in Acute Myeloid Leukemia

TURKISH JOURNAL OF HEMATOLOGY , cilt.29, sa.3, ss.223-224, 2012 (SCI-Expanded, Scopus, TRDizin) identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 305

4. YENİ TANI AKUT MİYELOİD LÖSEMİ HASTALARINDA PD-1 VE PD-L1 İFADESİNİN TEDAVİ SONUÇLARINA ETKİSİ

50.ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.126-127, (Tam Metin Bildiri) Creative Commons License

5. PRİMER GASTRİK LENFOMA: ÇOK MERKEZLİ ÇALIŞMA

50. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.28, (Özet Bildiri) Creative Commons License

7. PERİFERİK T HÜCRELİ LENFOMA TANILI HASTALARIN ANALİZİ: TEK MERKEZ DENEYİMİ

50. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.136-137, (Tam Metin Bildiri) Creative Commons License

8. STEROİD REFRAKTER GRAFT VERSUS HOST HASTALIĞINDA FOTOFEREZ KULLANIMI VE YANITLARININ DEĞERLENDİRİLMESİ, TEK MERKEZ DENEYİMİ

50. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.209, (Tam Metin Bildiri) Creative Commons License

10. GÜNCEL KLAVUZLAR EŞLİĞİNDE KLİNİKTE MASTOSİTOZ: TEK MERKEZ DENEYİMİ

50. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.119, (Tam Metin Bildiri) Creative Commons License

12. DİRENÇLİ BİR HEMORAJİK SİSTİK VAKASI

50. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.309-310, (Tam Metin Bildiri)

13. HİPEREOZİNOFİLİK SENDROM ALT TİPLERİNDE TANI VE TEDAVİ: RETROSPEKTİF TEK MERKEZLİ ÇALIŞMA

50.ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.120, (Tam Metin Bildiri) Creative Commons License

14. NÜKS DİRENÇLİ T HÜCRELİ LENFOMALARDA PRALATREKSAT KULLANIMI: TEK MERKEZ DENEYİMİ

50.Ulusal Hematoloji Kongresi, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.152-153, (Tam Metin Bildiri) Creative Commons License

15. KRONİK MİYELOİD LÖSEMİ HASTALARINDA BOSUTİNİB KULLANIMININ GERÇEK YAŞAM VERİLERİ: ULUSAL ÇOK MERKEZLİ ÇALIŞMA

50. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.118, (Özet Bildiri) Creative Commons License

22. İmmünsupressif hastada nadir etken: Ochrobactrum anthropi

İnfeksiyon Dünyası Çalıştayı 2024, Ankara, Türkiye, 17 - 21 Nisan 2024, (Özet Bildiri)

24. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPS/REFRACTORY LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 Nisan 2023, ss.457-458, (Özet Bildiri) identifier

25. ALPHA-1-ANTITRYPSIN EXPERIENCE FOR STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 Nisan 2023, ss.301-302, (Özet Bildiri) identifier

26. THE OUTCOME OF SECONDARY AML PATIENTS WITH PRIOR BREAST CANCER UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION IS AS GOOD AS DE NOVO AML

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 Nisan 2023, ss.181-182, (Özet Bildiri) identifier

27. EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES

The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians, Paris, Fransa, 23 Nisan 2023, cilt.58, ss.107, (Tam Metin Bildiri)

32. The Impact of CD34+Cell and Immunefector Cell Dose on Transplant Outcomes

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, cilt.140, ss.12673-12674, (Özet Bildiri) Creative Commons License identifier

33. Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti-CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, cilt.140, ss.4369-4370, (Özet Bildiri) Creative Commons License identifier

35. Atipik Prezentasyonlu AML Olgusu

9. Türk Tıbi Onkoloji Derneği Kongresi, Girne, Kıbrıs (Kktc), 18 - 22 Mayıs 2022, ss.132-133, (Özet Bildiri)

36. MORFOLOJİK LÖSEMİSİZ DURUMDA MLD (MORPHOLOGİC LEUKEMİA FREE STATE =MLFS) ALLOJENEİK HEMATOPOİETİK KÖK HÜCRE NAKLİ

14. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 10 - 12 Mart 2022, sa.177, ss.143-144, (Tam Metin Bildiri)

37. ALLOJENİK KÖK HÜCRE NAKLİ YAPILAN AML VE MDS TANILI HASTALARDA SKORLAMALARIN SAĞKALIMA ETKİSİ

14. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 10 - 12 Mart 2022, sa.178, ss.145-146, (Tam Metin Bildiri)

39. ERİŞKİN HASTALARDA TREOSULFAN BAZLI HAZIRLIK REJİMİ İLE ALLOJENİK KÖK HÜCRE NAKİL DENEYİMİ

14. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 10 Mart 2022, ss.143, (Tam Metin Bildiri)

46. HODGKİN LENFOMA TANILI HASTALARDA EKSTRANODAL TUTULUM VE YENİ TEDAVİLER

47. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 4 - 07 Kasım 2021, ss.346-347, (Tam Metin Bildiri)

47. Akut lenfoblastik Lösemi: Tanı ve Tedavi

9. Bozyaka Hematoloji Sempozyumu 19-20 Haziran 2021, İzmir, Türkiye, 19 Haziran 2021, ss.5-6, (Özet Bildiri)

48. PHENOTYPES OF BONE MARROW MONOCYTES IN STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA: A DESCRIPTIVE PILOT STUDY

8th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 21 - 22 Mayıs 2021, sa.63, ss.48, (Tam Metin Bildiri)

50. RELAPS/ REFRAKTER HODGKİN LENFOMA HASTALARINDA ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ: TEK MERKEZ DENEYİMİ

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 2 - 03 Nisan 2021, sa.52, ss.104-105, (Tam Metin Bildiri)

51. ALLOJENİK KÖK HÜCRE NAKLİ OLAN HASTALARDA CMV VİREMİSİ SIKLIĞI VE CMV VİRÜS ENFEKSİYONU İÇİN RİSK FAKTÖRLERİ- TEK MERKEZ DENEYİMİ

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 2 - 03 Nisan 2021, sa.67, ss.108-109, (Tam Metin Bildiri)

52. GRAFT VERSUS HOST HASTALIĞI SEBEBİ İLE RUXOLİTİNİB KULLANAN HASTALARDA ENFEKSİYON SIKLIĞININ BELİRLENMESİ

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 2 - 03 Nisan 2021, sa.137, ss.133-134, (Tam Metin Bildiri)

53. FLT-3 POZİTİF RELAPS REFRAKTER AML’DE POSTTRANSPLANT DÖNEMDE GİLTERİTİNİB DENEYİMİ: İKİ VAKA

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 2 - 03 Nisan 2021, sa.66, ss.151, (Tam Metin Bildiri)

55. COVID-19 Pandemisinde Allojeneik Hematopoetik Hücrelerin Kriyoprezervasyonu

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 Nisan 2021, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

59. MELFALAN JENERİKLERİ ARASINDAKİ TİFİLİT YAN ETKİ SIKLIĞININ KARŞILAŞTIRILMASI

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 Nisan 2021, (Tam Metin Bildiri)

60. THE IMPACT OF PRETRANSPLANT IMMUNOMODULATORY DRUGS ON CMV REACTIVATION

8 45 th International Congress on Leukemia Lymphoma Myeloma, Ankara, Türkiye, 21 Mayıs 2021, cilt.38, sa.71, ss.1-81, (Tam Metin Bildiri)

61. PATIENT RELATED FACTORS OVERRIDE LENALIDOMIDE MAINTENANCE AS A FACTOR OF SEVERITY FOR COVID-19 INFECTION

8th International Congress on Leukemia Lymphoma Myeloma, Ankara, Türkiye, 21 Mayıs 2021, cilt.38, ss.50, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

62. BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTO-SCT IN HIGH-RISK HODGKIN’S LYMPHOMA: MULTI-CENTER RETROSPECTIVE STUDY

8th International Congress on Leukemia Lymphoma Myeloma, Ankara, Türkiye, 21 Mayıs 2021, cilt.38, ss.1-81, (Tam Metin Bildiri)

65. NonHodgkin Lenfomaların Tedavisine Genel Yaklaşım

8. Bozyaka Hematoloji Günleri, Türkiye, 25 - 27 Aralık 2020, (Tam Metin Bildiri)

67. GRAFT VS HOST HASTALIĞINDA ALFA- 1 ANTİTRİPSİN DENEYİMİMİZ

46. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 28 - 31 Ekim 2020, sa.283, ss.117-118, (Tam Metin Bildiri)

75. MULTİPLE MYELOM’DA OTOLOG KÖK HÜCRE NAKLİ HAZIRLAMA REJİMİ OLARAK YÜKSEK DOZ MELFALAN’A BUSULFAN EKLENMESİNİN SONUÇLARI-TEK MERKEZ DENEYİMİ

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 2 - 03 Nisan 2021, sa.111, ss.126-127, (Tam Metin Bildiri)

76. Posagil, a new antifungal agent for prophylaxis among transplant patients

8th meet the expert or transplantation and cellular therapy, EBMT and ASTCT, İstanbul, Türkiye, 18 - 20 Eylül 2020

77. CD34+ Cell Subsets in Stem Cell Products and Their Relationship with Engraftment Kinetics

46th Annual Meeting of the European Society for Blood and Marrow Transplantation, 29 Ağustos 2020, (Tam Metin Bildiri)

80. AML TANISI İLE AKRABA DIŞI VERİCİDEN AHKHN YAPILAN HASTALARDA ATG KULLANIMININ NAKİL SONUÇLARINA ETKİSİ

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

82. Hematolojik malignitelerde nakil sonrası hematogon değerlerinin prognoza etkisi var mıdır?

12.Ulusal Kemik iliği transplantasyonu ve hücresel tedaviler kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

83. HEMORAJİK SİSTİT İÇİN YARGILANAN SİKLOFOSFAMİD SUÇSUZ BULUNDU: TEK MERKEZ 7 YILLIK DENEYİM

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

85. CD34 VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

86. CD34+ VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Muğla, Türkiye, 5 - 07 Mart 2020, sa.159, ss.60-61, (Tam Metin Bildiri)

89. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri) identifier identifier

90. Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri) identifier

92. Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT?

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.505-506, (Özet Bildiri) identifier

93. Results of a single center experience: An attempt to augment conditioning regimen in first autologous stem cell transplantation

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.500-501, (Özet Bildiri) identifier

94. Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.382, (Özet Bildiri) identifier

95. Blood group incompatibility in haplo-identical stem cell transplantation: Favor or unfavorable effect on the erythrocyte recovery?

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.368-369, (Özet Bildiri) identifier

97. CAN AUTOLOGOUS STEM CELL TRANSPLANTATION ABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, ss.45, (Tam Metin Bildiri)

102. SUCCESSFUL TREATMENT OF GRAFT FAILURE WITH SECOND ALLOGENEIC STEM CELL TRANSPLANTATION WITHOUT CONDITIONING REGIMEN

8th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, ss.75, (Tam Metin Bildiri)

103. Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri) identifier

104. Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri) identifier

105. Rational drug use

Expert of transplantation, Istanbul, Turkey, İstanbul, Türkiye, 12 - 13 Nisan 2019, (Tam Metin Bildiri)

106. Rtional drug use

hsshbIstanbul, 11 - 12 Nisan 2019, (Özet Bildiri)

107. CAN ELTROMBOPAG TREAT THE THROMBCYTOPENIA AFTER STEM CELL TRANSPLANTATION

7th International Congress on Leukemia Lymphoma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, (Tam Metin Bildiri)

108. MULTİPLE MYELOM HASTALARINDA OTOLOG PERİFERİK KÖK HÜCRE NAKLİ ESNASINDA GELİŞEN NÖTROPENİK ATEŞ

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 1 - 02 Mart 2019, sa.142, ss.130, (Tam Metin Bildiri)

109. Multipl Miyelom Olgularında Otolog Kök Hücre Naklinde Yüksek Doz Melfelana Bortezomib Eklenmesinin Tek Merkez Sonuçları

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 1 - 03 Mart 2019, (Tam Metin Bildiri)

111. Influence of Conditioning Regimens with Total Body Irradiation (TBI) on Graft Versus Host Disease and Graft Versus Leukemia Effect Following Donor Lymphocyte Infusions (DLI)

Transplant and Cell Therapy Meeting / Combined Annual Meetings of the American-Society-for-Blood-and-Marrow-Transplantation (ASBMT) and the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR), Texas, Amerika Birleşik Devletleri, 13 - 24 Şubat 2019, cilt.25, (Özet Bildiri) identifier

112. PRİMER İMMUN YETMEZLİKLİ ERİŞKİN HASTALARDA ALLOJENEİK NAKİL DENEYİMİ

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 01 Mart 2019, (Özet Bildiri)

115. Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri) identifier

117. Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri) identifier identifier

121. Is post-transplant albumin a predictor of early transplant complications?

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.344-345, (Özet Bildiri) identifier

122. Donor lymphocyte infusion after salvage chemotherapy in relapsed acute myeloblastic leukemia patients after allogeneic stem cell transplantation

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.161-162, (Özet Bildiri) identifier

123. Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.338, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

124. Ruxolitinib in steroid refractory GVHD treatment: single center experience

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.448-449, (Özet Bildiri) identifier

126. Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.272-273, (Özet Bildiri) identifier

128. Hodgkin Lenfoma’xxda Yeni Ajanların Kullanımı

4. Ege Hematoloji Onkoloji Kongresi, Türkiye, 16 - 18 Mart 2018, (Tam Metin Bildiri)

129. AKUT GRAFT VERSUS HOST HASTALIĞI KLİNİK SONUÇLARI: TEK MERKEZ DENEYİMİ

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 01 Mart 2018, (Özet Bildiri)

131. Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma

Blood and Marrow Transplantion Tandem Meetings of the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR) / American-Society-for-Blood-and-Marrow-Transplantation (ASBMT), Utah, Amerika Birleşik Devletleri, 21 - 25 Şubat 2018, cilt.24, (Özet Bildiri) identifier

133. Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130, (Özet Bildiri) identifier

134. Age Is Not Important for Autologous Peripheral Hematopoietic Stem Cell Transplantation in Multiple Myeloma

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130, (Özet Bildiri) identifier

136. Chronic eosinophilic leukemia

4th aegean hematology oncology symposium 2017, 21 - 24 Eylül 2017, (Özet Bildiri)

137. Is mastocytosis really rare disease? Three case experience

Congress of the European-Academy-of-Allergy-and-Clinical-Immunology, Helsinki, Finlandiya, 17 - 21 Haziran 2017, cilt.72, ss.448-450, (Özet Bildiri) identifier

138. Peripheral blood stem cell mobilization and collection from elderly patients (>= 65 years) with multiple myeloma: A single center experience

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) identifier

139. The outcome of haploidentical hematopoietic cell transplantations

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) identifier

140. The effect of donor Epstein-Barr virus (EBV) seropositivity on graft versus host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (Allo-HSCT)

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) identifier

145. Evaluating peritransplant albumin decline as a predictor of acute graft versus host disease

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) identifier

146. Large unstained cell percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) Sürdürülebilir Kalkınma identifier identifier identifier

147. HLA C1/C1 homozygosity decreases relapse rate after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in acute myeloid leukemia (AML) patients

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) identifier

149. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in advanced age adults: is it possible to transplant safely?

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) identifier

150. Herpes simplex virus (HSV) infection in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT)

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) identifier

151. AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: SINGLE CENTER EXPERIENCE

22nd Congress of the European-Hematology-Association, Madrid, İspanya, 22 - 25 Haziran 2017, cilt.102, ss.865, (Özet Bildiri) identifier

152. NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY

22nd Congress of the European-Hematology-Association, Madrid, İspanya, 22 - 25 Haziran 2017, cilt.102, ss.84-85, (Özet Bildiri) identifier

153. A single center experience with two decades of follow-up on patients with hairy cell leukemia.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri) identifier

154. Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri) identifier

159. Relaps / Refrakter KLL: Nereye Kadar Tedavi Edelim?

3. Ege Hematoloji Onkoloji Kongresi, Türkiye, 17 - 19 Mart 2017, (Özet Bildiri)

160. Kemik İliği Transplantasyonu Sonrası Gelişen SARKOİDOZ

Ulusal Akciğer Sağlığı Kongresi, Türkiye, 15 - 19 Mart 2017, (Özet Bildiri)

161. Management and Outcome of Central Nerve System(CNS) Involvement in Acute Lymphoblastic Leukemia

BMT Tandem Meetings, orlando, Amerika Birleşik Devletleri, 22 - 26 Şubat 2017, cilt.23, ss.251, (Özet Bildiri)

165. Does Donor Epstein-Barr Virus (EBV) Seropositivity Affect Recipient's Risk of Graft Versus Host Disease (GVHD) in Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT)?

58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 3 - 06 Aralık 2016, cilt.128, (Özet Bildiri) identifier

166. Does Hypogammaglobulinemia at Diagosis Effects Survival and Infection Risk in Chronic Lymphocytic Leukemia (CLL)?

58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 3 - 06 Aralık 2016, cilt.128, (Özet Bildiri) identifier

179. MANAGEMENT AND OUTCOME OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PRE AND POST TRANSPLANT

21st Congress of the European-Hematology-Association, Copenhagen, Danimarka, 9 - 12 Haziran 2016, cilt.101, ss.356, (Özet Bildiri) identifier

180. EXTRACORPOREAL PHOTOPHERESIS: SAFE AND EFFECTIVE FOR THE TREATMENT OF MYCOSIS FUNGOIDES

21st Congress of the European-Hematology-Association, Copenhagen, Danimarka, 9 - 12 Haziran 2016, cilt.101, ss.393-394, (Özet Bildiri) identifier

182. OUR APPROACH TO HAIRY CELL LEUKEMIA (HCL): 31 YEARS OF EXPERIENCE

21st Congress of the European-Hematology-Association, Copenhagen, Danimarka, 9 - 12 Haziran 2016, cilt.101, ss.442, (Özet Bildiri) identifier

183. IS IT POSSIBLE TO DIAGNOSE LOW RISK MYELODYSPLASTIC SYNDROME (MDS) BY FLOW CYTOMETRY?

21st Congress of the European-Hematology-Association, Copenhagen, Danimarka, 9 - 12 Haziran 2016, cilt.101, ss.506, (Özet Bildiri) identifier

185. Successful treatment in primary central nervous system lymphoma.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) identifier

186. THERAPEUTIC PLASMA EXCHANGE FOR THROMBOTIC MICROANGIOPATHY

24th Biennial International Congress on Thrombosis / EMLTD Congress, İstanbul, Türkiye, 4 - 07 Mayıs 2016, cilt.141, (Özet Bildiri) identifier

187. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) identifier

188. THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBULINURIA PATIENTS: SINGLE CENTER EXPERIENCE

24th Biennial International Congress on Thrombosis / EMLTD Congress, İstanbul, Türkiye, 4 - 07 Mayıs 2016, cilt.141, (Özet Bildiri) identifier

189. ARE AGE AND JAK2V617F MUTATION RELATED TO THROMBOSIS IN CHRONIC MYELOPROLIFERATIVE DISEASES?

24th Biennial International Congress on Thrombosis / EMLTD Congress, İstanbul, Türkiye, 4 - 07 Mayıs 2016, cilt.141, (Özet Bildiri) identifier

190. THERAPEUTIC THROMBOCYTAPHERESIS: HIGHER PLATELET COUNTS SHOULD MATTER

24th Biennial International Congress on Thrombosis / EMLTD Congress, İstanbul, Türkiye, 4 - 07 Mayıs 2016, cilt.141, (Özet Bildiri) identifier

191. Thrombosis in Paroxysmal Nocturnal Hemoglobinuria Patients: Single Center Experience

24th Biennial International Congress on Thrombosis, İstanbul, Türkiye, 1 - 07 Mayıs 2016, cilt.141, ss.72, (Özet Bildiri) identifier

195. Efficacy of High Dose Corticosteroid Premedication for the Prevention of Anti-thymocyte Globulin Related Side Effects

42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Valencia, İspanya, 3 - 06 Nisan 2016, cilt.51, (Özet Bildiri) identifier

196. Regrafting For Primary and Secondary Graft Failure

42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Valencia, İspanya, 3 - 06 Nisan 2016, cilt.51, (Özet Bildiri) identifier

198. Clinical Characteristics and Frequency of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation

42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Valencia, İspanya, 3 - 06 Nisan 2016, cilt.51, (Özet Bildiri) identifier

200. The Efficacy of Tyrosine Kinase Inhibitors with Steroid As First Line Induction Therapy in Ph Acute Lymphoblastic Leukemia

The Efficacy of Tyrosine Kinase Inhibitors with Steroid As First Line Induction Therapy in Ph+ Acute Lymphoblastic Leukemia, 5 - 07 Aralık 2014, (Özet Bildiri)

203. Extracorporeal Photopheresis for the Treatment of Mycosis Fungoides

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) identifier

204. Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) identifier

205. Is Initial CD3+T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) identifier

207. Positive Impact of Chronic Graft-Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) identifier

212. Waldenström Makroglobulinemisinde Tek Merkez Deneyimi

41. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 21 - 24 Ekim 2015, ss.106-107, (Özet Bildiri)

222. Extracorporeal Photopheresis for Mycosis Fungoides Is it benefical

77th Annual Meeting of the Japanese Society of Hematology, October 16-18, 2015, Kanazawa, Japan., 16 - 18 Ekim 2015

224. Is autologous stem cell transplantation successful in elderly fit patients 60 years with non Hodgkin lymphoma

13th International Conference on Malignant Lymphoma. Palazzo dei Congresei, Lugano, Switzerland, 17 - 20 Haziran 2015, (Özet Bildiri)

228. POST TRANSPLANT ERYTHROCYTOSIS IN ELEVEN CASES

20th Congress of European-Hematology-Association, Vienna, Avusturya, 11 - 14 Haziran 2015, cilt.100, ss.616, (Özet Bildiri) identifier

229. FERTILITY IN OUR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: RESULTS FOR 23 YEARS OF EXPERIENCE

20th Congress of European-Hematology-Association, Vienna, Avusturya, 11 - 14 Haziran 2015, cilt.100, ss.602, (Özet Bildiri) identifier

230. ALLOGENEIC STEM-CELL TRANSPLANTATION FOR ADVANCED MYCOSIS FUNGOIDES/SEZARY SYNDROME

20th Congress of European-Hematology-Association, Vienna, Avusturya, 11 - 14 Haziran 2015, cilt.100, ss.662-663, (Özet Bildiri) identifier

235. Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Allo HSCT A Single Center Experience 41st Annual Meeting of the European Society for Blood and

(Allo-HSCT): A Single Center Experience. 41st Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, 22-25 Mayıs 2015., 22 - 25 Mayıs 2015, (Tam Metin Bildiri)

236. AUTOLOGOUS STEM CELL TRANSPLANTATION AND PRIMARY SYSTEMIC LIGHT CHAIN AL AMYLOIDOSIS SINGLE CENTER EXPERIENCE

5th International Congress on lymphoma Leukemia Myeloma, İstanbul, Turkey, 21 - 23 Mayıs 2015, (Özet Bildiri)

237. Allogeneic Stem Cell Transplantation for Hodgkin and non Hodgkin Lymphoma

5th International Congress on Lymphoma Leukemia Myeloma, İstanbul, Turkey, 21-23 May 2015. Turkish Society of Hematology, Proceedings & Abstract Book, abstract # 0109, poster # PS-101 pp 175., 21 - 23 Mayıs 2015

238. AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS 60 YEARS WITH MYELOMA OR LYMPHOMA

5th International Congress on Lymphoma Leukemia Myeloma, İstanbul, Turkey, 21 - 23 Mayıs 2015, (Özet Bildiri)

239. Azacitidine in combination with ATRA, valproic acid in elderly AML patients.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

240. CML leukemic stem cell (CML LSC): Its existence in patients who achieved cytogenetic/molecular response under treatment of TKI.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

241. Does chronic lymphocytic leukemia occur in younger adults in Turkey?

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

242. Allogeneic stem cell transplantation results in our myelodysplastic syndrome (MDS) patients.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

257. Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT): A Single Center Experience

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

258. Is it possible to overcome the catastrophic complications of Hematopoietic Stem Cell Transplantation (HSCT) using Plasma Exchange (PE)?: A Single Center's Experience

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, ss.5581-5582, (Özet Bildiri) identifier

259. Generic (Bioequivalent) Melphalan Has Similar Efficacy and Toxicity but Lower Cost in the Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

260. Different Doses of Anti-Thymocyte Globulin (ATG) in the Conditioning Regimen for Allogeneic Hematopoetic Stem Cell Transplantation

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, (Özet Bildiri) identifier

261. Are there any optimal cell doses for graft repopulation in the Bone Marrow-Derived Allogeneic Hematopoietic Stem Cell Transplantations?

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

262. Age, Cytopenia at Diagnosis and History of Hypertension are associated with Stem Cell Mobilization Failures Among Patients with Multiple Myeloma

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

263. Allogeneic Stem-Cell Transplantation for advanced mycosis fungoides/Sezary syndrome: Single-center experience

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, ss.5618-5619, (Özet Bildiri) identifier

264. WHICH TYPE OF THE DRESSING AT THE INSERTION SITE MAY AFFECT THE RATE OF CATHETER INFECTION: GAUZE OR TRANSPARENT SEMIPERMEABLE DRESSING?

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, ss.5532, (Özet Bildiri) identifier

265. Is there an optimum CD3+T cell dose for donor lymphocyte infusion?

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, ss.5598, (Özet Bildiri) identifier

266. Allogeneic Stem-Cell Transplantation for Hodgkin and non-Hodgkin Lymphoma: Single-center experience

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, ss.5619, (Özet Bildiri) identifier

267. Autologous Stem Cell Transplantation in Elderly Patients ( >=60 years) with Myeloma or Lymphoma: Single Center Experience

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, ss.5622, (Özet Bildiri) identifier

268. The relapse in acute leukemia after the allogeneic hematopoetic stem cell transplantation: No approaches have been superior yet

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

269. Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Single Centre Experience

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

270. Erythrocytosis following allogeneic hematopoietic stem cell transplantation in six cases

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

271. Impact of Pre-transplant Serum Ferritin on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

272. Prognosis of Acute Leukemia Patients with Active Disease Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

273. Chronic Myeloproliferative Disease in Geriatric Patients

77th Annual Meeting of the Japanese Society of Hematolog, 16 - 18 Ekim 2015, (Tam Metin Bildiri)

274. Treatment Approaches in Acute Leukemia Patients Relapsing Following Allogeneic Hematopoietic Stem Cell Transplantation

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

275. Do FMS-like Tyrosine Kinase 3 and Nucleophospmin 1 Gene Mutations Really Effect Survival in Acute Myeloid Leukemia ?

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

276. The Efficacy of Tyrosine Kinase Inhibitors with Steroid As First Line Induction Therapy in Ph plus Acute Lymphoblastic Leukemia

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

277. Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience of a Single Center

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

278. Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

279. Fertility in Our Allogeneic Hematopoietic Stem Cell Transplant Patients

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

280. Is R-CODOX-M/IVAC Inferior to Other Regimens in Burkitt's Lymphoma: A Single Center Experience

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

282. Cytopenia at Diagnosis Impairs Stem Cell Mobilization Among Patients with Multiple Myeloma

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

287. STEM CELL MOBILIZATION IN ELDERLY MULTIPLE MYELOMA PATIENTS: SINGLE CENTER EXPERIENCE

19th Congress of the European-Hematology-Association, Milan, İtalya, 12 - 15 Haziran 2014, cilt.99, ss.721, (Özet Bildiri) identifier

288. HYPERVISCOSITY IN RENAL TRANSPLANTATION RECIPIENTS

51st Congress of the European-Renal-Association(ERA)/European-Dialysis-and-Transplant-Association (EDTA), Amsterdam, Hollanda, 31 Mayıs - 03 Haziran 2014, cilt.29, ss.326, (Özet Bildiri) identifier

290. A novel conditoning regimen for primary CNS lymphoma: high dose rituximab, cyclophosphamide, etoposide and BCNU (RCVB)

39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), London, Kanada, 7 - 10 Nisan 2013, cilt.48, (Özet Bildiri) identifier

291. FACTORS INFLUENCING HYPERVISCOSITY IN MAINTENANCE HEMODIALYSIS PATIENTS

49th Congress of the European-Renal-Association/European-Dialysis-and-Transplant-Association (ERA-EDTA), Paris, Fransa, 24 - 27 Mayıs 2012, cilt.27, ss.516, (Özet Bildiri) identifier

292. Oral cavity chronic-graft-versus host disease after allogeneic haematopoietic stem cell transplantation

38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Geneva, İsviçre, 1 - 04 Nisan 2012, cilt.47, (Özet Bildiri) identifier

298. Allogeneic haematopoietic cell transplantation in acute myeloblastic laeukemia: Ibni Sina experience (1989-2004)

31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, Prague, Çek Cumhuriyeti, 20 - 23 Mart 2005, cilt.35, (Özet Bildiri) identifier

300. High-dose therapy is given to multiple myeloma patients with similar clinical characteristics to those in conventional chemotherapy and improves survival in multiple myeloma: a retrospective analysis from a single centre

30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, İspanya, 28 - 31 Mart 2004, cilt.33, (Özet Bildiri) identifier

304. Comparative analysis of molecular response following interferon-alpha, imatinib mesilate or allogeneic stem cell transplantation (ASCT): best response is obtained with ASCT in chronic myeloid leukemia

29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31, (Özet Bildiri) identifier

305. Kinetics of chimerism in sex-mismatched allogeneic hematopoietic cell transplantation with reduced-intensity conditioning

29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31, (Özet Bildiri) identifier
Kitaplar 11

1. Akut Lösemilerde Allojeneik Hematopoetik Kök Hücre Nakli Sonrası İdamenin Yeri ve Önemi

Türkiye Klinikleri Hematoloji- Akut Lösemiler, Pervin Topçuoğlu,Selami Koçak Toprak, Editör, Türkiye Klinikleri Yayınevi, Ankara, ss.79-85, 2022 Creative Commons License

2. Akut Lösemilerde Allojeneik Hematopoetik Kök Hücre Nakli Sonrası İdamenin Yeri ve Önemi

Akut Lösemiler - 2022, Topçuoğlu Pervin, Toprak Selami Koçak, Editör, Türkiye Klinikleri, Ankara, ss.79-85, 2022

4. Coagulation Tests as a Biomarker during the COVID-19 Course

COVID-19 Seyrinde Biyobelirteç Olarak Koagulasyon Testleri, Meltem Kurt Yüksel, Editör, Türkiye Klinikleri Yayınevi, Ankara, ss.24-26, 2021

6. COVID-19 Sürecinde Biyobelirteç Olarak Koagulasyon Testleri

COVID -19 Sürecinde Biyobelirteçlerin Klinik Pratikte Kullanımı - 2021, Kurt Yüksel, Meltem, Editör, Türkiye Klinikleri, Ankara, ss.24-26, 2021

7. Chapter-8 Treatment of Elderly Patients with Multiple Myeloma

Textbook Of Multiple Myeloma And Other Plasma Cell Neoplasms, Tombak Anıl, Editör, İstanbul Tıp Kitabevleri, Ankara, ss.165-184, 2021

8. Düşük Riskli Miyelodisplastik Sendrom Yönetimi ve Tedavi Stratejileri

Miyelodisplastik Sendrom - 2021, Çetiner, Mustafa, Editör, Türkiye Klinikleri, Ankara, ss.32-41, 2021

9. Editöryal

Hematoloji ve COVID-19 - 2020 (Kitap Editörlüğü), İlhan Osman, Toprak Selami Koçak, Editör, Türkiye Klinikleri, Ankara, ss.1-116, 2020 Sürdürülebilir Kalkınma

10. COVID-19 ve İlaç/Aşı Klinik Çalışmaları Clinical Researches of Drug Vacccines on COVID-19

Hematoloji ve COVID-19 - 2020, İlhan Osman, Toprak Selami Koçak, Editör, Türkiye Klinikleri, Ankara, ss.103-107, 2020 Sürdürülebilir Kalkınma

11. EXTRACORPOREAL PHOTOCHEMOTERAPY (ECP) IN DERMATOLOGY

IMMUNOMODULATORY ANDIMMUNSUPPRESSIVEDRUGS IN DERMATOLOGY, Prof. Dr. Ümit TÜRSEN, Editör, AKADEMISYEN TIP KITABEVI, Ankara, ss.307-312, 2016
Metrikler

Yayın

450

Yayın (WoS)

211

Yayın (Scopus)

97

Atıf (WoS)

610

H-İndeks (WoS)

12

Atıf (Scopus)

611

H-İndeks (Scopus)

12

Atıf (Scholar)

119

H-İndeks (Scholar)

7

Atıf (TrDizin)

2

H-İndeks (TrDizin)

1

Atıf (Diğer Toplam)

2

Proje

7

Tez Danışmanlığı

8

Açık Erişim

24
BM Sürdürülebilir Kalkınma Amaçları